Nov 20 Webinar: NS Pharma Provides Viltolarsen Update
NS Pharma will join Parent Project Muscular Dystrophy for a webinar Wednesday, November 20 at 1pm eastern to provide the community with an overview of its investigational drug, viltolarsen (NS-065/NCNP-01), including its mechanism of action and regulatory status. NS Pharma will also provide an update on the viltolarsen clinical program, including the completed Phase 1, Phase 1/2, and Phase 2 studies. They will also discuss the viltolarsen Phase 3 trial (RACER53), including anticipated countries where the study will be conducted, study design, description of the endpoints, and inclusion/exclusion criteria.
- Abby Bronson
Senior Vice President, Research Strategy
Parent Project Muscular Dystrophy
- Angela Melia
Associate Director, Research & Development
- Paula R. Clemens, MD
Study Chair, NS-065/NCNP-01-201 study and NS-065/NCNP-01-202 study
Medical Director, CINRG
Professor and Vice Chair, Neurology, University of Pittsburgh School of Medicine
Division Chief, Neurology Service, VA Pittsburgh Healthcare System
Please submit questions in advance to firstname.lastname@example.org (subject line: NS Pharma Webinar) by Monday, November 18 at 12pm eastern.